Drugs / ABI-009
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03657420 | May 2019 → Sep 2021 | plasma cell myeloma | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03646240 | Jul 2018 → Aug 2022 | epilepsy | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00635284 | Dec 2007 → Jun 2011 | cancer | Celgene Corporation | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03747328 | Apr 2022 → Dec 2024 | Leigh syndrome | Aadi Bioscience, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03670030 | Nov 2018 → Jan 2021 | neuroendocrine neoplasm | Robert Ramirez | Terminated | No outcome recorded Stop: Enrollment |
| Phase not stated1 trial | ||||||
| — | NCT03817515 | — | neoplasm with perivascular epithelioid cell differentiation, tuberous sclerosis 1, tuberous sclerosis 2 | Aadi Bioscience, Inc. | Approved for marketing | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657420 ↗ |
| Known as | Nab-rapamycin | “ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)” NCT03646240 ↗ |
| Known as | Nab-sirolimus | “ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome” NCT03747328 ↗ |
| Action | Inhibit | “a mammalian target of rapamycin \[mTOR\] inhibitor” NCT03646240 ↗ |
| Route | Intravenous | “ABI-009 is given intravenously on days 1, 8, and 15” NCT03657420 ↗ |
| Target | MTOR | “a mammalian target of rapamycin \[mTOR\] inhibitor” NCT03646240 ↗ |